Eli Lilly and Company (NYSE:LLY) Stock Price Up 1.4%

Shares of Eli Lilly and Company (NYSE:LLY) rose 1.4% during mid-day trading on Thursday . The stock traded as high as $793.67 and last traded at $788.72. Approximately 933,417 shares were traded during trading, a decline of 71% from the average daily volume of 3,196,724 shares. The stock had previously closed at $778.18.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of research analyst reports. Wells Fargo & Company upped their target price on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 target price on shares of Eli Lilly and Company in a report on Tuesday, February 20th. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective on the stock. in a research note on Wednesday, February 21st. JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Finally, BMO Capital Markets lifted their target price on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research note on Wednesday, February 7th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $689.52.

Eli Lilly and Company Stock Down 0.0 %

The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm has a 50-day simple moving average of $730.97 and a two-hundred day simple moving average of $637.01. The company has a market cap of $739.19 billion, a PE ratio of 134.56, a P/E/G ratio of 1.70 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the previous year, the company posted $2.09 EPS. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. Research analysts anticipate that Eli Lilly and Company will post 12.42 earnings per share for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the sale, the insider now directly owns 99,333,810 shares in the company, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have sold 195,055 shares of company stock worth $125,254,657 over the last quarter. 0.13% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Lipe & Dalton acquired a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $26,000. Thompson Investment Management Inc. bought a new stake in shares of Eli Lilly and Company in the 3rd quarter worth about $27,000. Retirement Group LLC raised its stake in shares of Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock valued at $27,000 after purchasing an additional 35 shares in the last quarter. Tidemark LLC bought a new position in shares of Eli Lilly and Company during the fourth quarter worth about $29,000. Finally, Core Wealth Advisors Inc. increased its holdings in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after buying an additional 32 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.